{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:03:59Z","timestamp":1790190239184,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vobramitamab duocarmazine is an investigational antibody\u2013drug conjugate (ADC) targeting B7 homolog 3 (B7\u2010H3) with a cytotoxic duocarmycin\u2010based DNA\u2010alkylating payload. This study evaluated its safety and antitumor activity in advanced solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this phase 1\/2 trial (CP\u2010MGC\u2010018\u201001\/NCT03729596), vobramitamab duocarmazine was evaluated at 0.5\u20134.0 mg\/kg intravenously every 3 weeks. The multicohort tumor\u2010expansion phase focused on metastatic castration\u2010resistant prostate cancer (mCRPC), lung, breast, melanoma, and squamous head and neck carcinomas. Primary end points were safety and tolerability. Secondary end points included pharmacokinetics, immunogenicity, and antitumor activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across vobramitamab duocarmazine\u2013treated patients, 97.9% (140 of 143) experienced treatment\u2010related adverse events (TRAEs) of all grades; the grade \u22653 TRAE rate was 65.0% (93 of 143). With two dose\u2010limiting toxicities in patients receiving 4.0 mg\/kg (grade 4 afebrile neutropenia and grade 3 fatigue), the recommended dose for expansion was 3.0 mg\/kg. Among all patients treated at 3.0 mg\/kg, the rate of grade \u22653 TRAEs was 65.3% (79 of 121) and the confirmed objective response rate (ORR) was 7.2% (seven of 97), with a 6.3\u2010month median duration of response (DOR). Among patients with mCRPC receiving 3.0 mg\/kg, the confirmed ORR was 8.3% (two of 24), with a 5.3\u2010month median DOR; the confirmed prostate\u2010specific antigen with a \u226550% decline from the baseline response rate was 43.9% (18 of 41), with a 6.2\u2010month median DOR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Vobramitamab duocarmazine demonstrated modest antitumor activity across tumor types, with the most pronounced activity in mCRPC. Treatment was limited by toxicity, particularly pleural effusions and fatigue, which restricted dosing duration. Study treatment was discontinued to refocus on mCRPC in a randomized phase 2 study (TAMARACK\/NCT05551117), which was later discontinued after assessment of the vobramitamab duocarmazine safety and efficacy profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.70544","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:08:32Z","timestamp":1784790512000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vobramitamab duocarmazine, an anti\u2013B7\u2010H3 antibody\u2013drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-8542","authenticated-orcid":false,"given":"Eugene","family":"Shenderov","sequence":"first","affiliation":[{"name":"Medical Oncology Johns Hopkins Medicine\u2013The Sidney Kimmel Comprehensive Cancer Center  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish R.","family":"Sharma","sequence":"additional","affiliation":[{"name":"The START Center for Cancer Research\u2013Midwest  Grand Rapids Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Garralda","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron Institute of Oncology Vall d\u2019Hebron University Hospital  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Powderly","sequence":"additional","affiliation":[{"name":"Carolina BioOncology Institute  Huntersville North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"\u0141ugowska","sequence":"additional","affiliation":[{"name":"Centre of Excellence in Precision Cancer Medicine Maria Sk\u0142odowska\u2010Curie National Research Institute of Oncology  Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Spira","sequence":"additional","affiliation":[{"name":"Research Institute Virginia Cancer Specialists  Fairfax Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc Cucurull","family":"Salamero","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Institut Catal\u00e0 d'Oncologia  Badalona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sekwon","family":"Jang","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Inova Schar Cancer Institute  Fairfax Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Cosman","sequence":"additional","affiliation":[{"name":"Medical Oncology St Vincent\u2019s Hospital Sydney  Darlinghurst New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Shen","sequence":"additional","affiliation":[{"name":"Jonsson Comprehensive Cancer Center University of California Los Angeles  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Cancer Services Princess Alexandra Hospital  Brisbane Queensland Australia"},{"name":"The University of Queensland  St Lucia Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr J.","family":"Wysocki","sequence":"additional","affiliation":[{"name":"Department of Oncology Jagiellonian University Medical College Hospital  Krakow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodryg","family":"Ramlau","sequence":"additional","affiliation":[{"name":"Medical Oncology Poznan University of Medical Sciences  Poznan Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center University of Minnesota  Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Weickhardt","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Olivia Newton\u2010John Cancer Wellness and Research Centre  Heidelberg Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"\u017bo\u0142nierek","sequence":"additional","affiliation":[{"name":"Department of Clinical Trials Szamocka Hospital Lux Med Oncology  Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-829X","authenticated-orcid":false,"given":"Emiliano","family":"Calvo","sequence":"additional","affiliation":[{"name":"Early Phase Clinical Trials START Madrid Centro Integral Oncol\u00f3gico Clara Campal  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enxu","family":"Zhao","sequence":"additional","affiliation":[{"name":"MacroGenics Inc  Rockville Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chet","family":"Bohac","sequence":"additional","affiliation":[{"name":"MacroGenics Inc  Rockville Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Ward","sequence":"additional","affiliation":[{"name":"MacroGenics Inc  Rockville Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Mallesara","sequence":"additional","affiliation":[{"name":"Medical Oncology Calvary Mater Hospital Newcastle  Waratah New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571\u2010023\u201000850\u20102"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767\u20109764.crc\u201023\u20100546"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.mct\u201020\u20100116"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002284\u2010w"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701006"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201015\u20102428"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.41105"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585\u2010025\u201001014\u2010w"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.5015"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1876"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.5051"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010025\u201003600\u20102"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.18470"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864\u2010025\u201001317\u20105"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp500781a"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392\u2010022\u201000947\u20107"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.086132"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1515\/bmc\u20102022\u20100051"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.12.007"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102023\u2010007174"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70544","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70544","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70544","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:55:31Z","timestamp":1785858931000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":21,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,8,1]]}},"alternative-id":["10.1002\/cncr.70544"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70544","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"2026-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70544"}}